ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

CLLS Cellectis SA

3.05
-0.05 (-1.61%)
Pre Mercado
Última actualización: 03:57:04
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Cellectis SA CLLS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.05 -1.61% 3.05 03:57:04
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.10
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
06/5/202405:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/5/202401:00GLOBECellectis Announces Completion of the Additional Equity..
02/5/202415:30GLOBECellectis Appoints Arthur Stril as Interim Chief Financial..
29/4/202415:46GLOBECellectis Reports Financial Results for the Fourth Quarter..
22/4/202415:30GLOBECellectis Presents Novel TALEN® Editing Processes Enabling..
10/4/202415:30GLOBECellectis Publishes a Novel Intronic Gene Editing Approach..
08/4/202415:30GLOBECellectis Announces Two Poster Presentations on Novel TALEN®..
16/1/202415:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/1/202415:30GLOBECellectis announces the drawdown of the second tranche of..
22/12/202315:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/12/202315:30GLOBECellectis Reports Results from Shareholders Meeting Held on..
22/12/202315:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202315:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/11/202315:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/11/202315:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/11/202315:30GLOBECellectis’ Shareholders Meeting to be Held on December 22,..
15/11/202306:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/11/202301:30GLOBECellectis Announces the execution of the Subsequent..
09/11/202315:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202315:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202315:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202315:30GLOBECellectis Reports Financial Results for Third Quarter and..
02/11/202315:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202315:30GLOBECellectis to Present Preliminary Results of NATHALI_01 and..
01/11/202315:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202315:30GLOBECellectis to Report Third Quarter 2023 Financial Results on..
01/11/202314:15APSBiotech Shares Soar After AstraZeneca Stake & Research..
01/11/202306:52DJNCellectis Shares Soar Premarket on AstraZeneca Deal
01/11/202306:51DJNCellectis Shares Soar Premarket on AstraZeneca Deal
01/11/202305:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202303:17DJNAstraZeneca to Invest $245 Million in Deal With Cellectis
01/11/202302:00GLOBECellectis Announces Strategic Collaboration and Investment..
31/10/202316:10EDGAR2Form 20-F/A - Annual and transition report of foreign..
31/10/202316:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202315:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202315:30GLOBECellectis Presents Pre-Clinical Data on Multi-armored..
24/10/202315:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/10/202315:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/10/202315:30GLOBECellectis and Imagine Institute Publish A Proof-Of-Concept..
27/9/202315:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/9/202315:30GLOBECellectis to Present Pre-Clinical Data on Multi-armored..
05/9/202315:32EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
07/8/202316:05EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/8/202315:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/8/202315:30GLOBECellectis Provides Full Report for Second Quarter 2023..
07/8/202315:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202315:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202315:30GLOBECellectis Provides Business Updates and Preliminary..
27/7/202315:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/7/202315:30GLOBECellectis to Report Second Quarter 2023 Financial Results on..

Su Consulta Reciente

Delayed Upgrade Clock